
Bundesbank boss Joachim Nagel sees signs of a stronger economic recovery than expected in the summer.
AI-generated summary
The Bundesbank had forecast in June that real GDP would grow by 0.5 percent this year and by 0.8 percent in 2027.
Berlin. The Bundesbank is more confident about the German economy than it was in the summer. “Our interim assessments point to a stronger recovery than we expected in the summer,” said Bundesbank boss Joachim Nagel on Wednesday at a Latvian Central Bank conference in Riga.
In their Germany forecast presented in June, the experts at the Bundesbank predicted that calendar-adjusted real gross domestic product (GDP) would grow by 0.5 percent in the current year and by 0.8 percent in 2027. The German central bank plans to publish its next full forecast in December. From Nagel's point of view, the fact that there are now signs of a stronger economic recovery than expected in June is encouraging, but no reason to feel safe.
Fiscal policy is unlikely to noticeably increase growth potential. According to Bundesbank estimates, additional public investments in infrastructure will strengthen production potential, but only to a very moderate extent. However, additional defense spending is not expected to make a positive contribution to growth in production potential in the foreseeable future.
“This is precisely why Germany must make progress with structural reforms,” warned Nagel. Germany must expand its labor supply, make the energy transition more efficient and create better conditions for investment and innovation. “I am confident that the incumbent federal government will continue to tackle these challenges resolutely,” emphasized the Bundesbank boss.
AI outlook — possibilities, not facts
Publication of the next full Bundesbank forecast in December
Very likely · Within months

A historical graphic from the 19th century predicts stock market developments and recommends selling stocks in 2026. Financial expert Andreas Hackethal classifies this as pure coincidence and astrology.

Despite oil flowing through the Strait of Hormuz again, kerosene remains extremely expensive at $1,550 per ton. European airlines such as Ryanair and Lufthansa are seeing falling hedges for 2027, leading to drastic price increases, according to industry bosses.

The US FDA has approved Bayer's stroke drug Asundexian. The drug in the new class of active ingredients is intended to compensate for the loss in sales of its predecessor Xarelto and strengthen Bayer's US business, while Bayer shares rose on the stock market.

The prospect of continued strong semiconductor demand and optimistic industry surveys have driven the Japanese stock market. In China, meanwhile, interest rate concerns in the USA and rising oil prices dampened buying sentiment.

The weight loss pill Wegovy from Novo Nordisk has a slow start in Germany: in September only 16,000 tablet packs were delivered, compared to 391,000 syringes. Complex income rules and costs of up to 270 euros per month probably explain the reluctance. Novo Nordisk is therefore launching a campaign with national soccer coach Jürgen Klopp.

Numerous international companies such as Nissan, SFC Energy, Voestalpine and Brenntag have presented their quarterly figures. While some companies were able to make gains thanks to special effects or strong demand, costs and crises weighed on the balance sheets of others.